The precursor for the acid-stimulating hormone gastrin provides a useful model for studies of post-translational processing because defined sites of cleavage, amidation, sulphation and phosphorylation occur within a dodecapeptide sequence. The factors determining these post-translational processing events are still poorly understood. We have used brefeldin A, which disrupts transport from rough endoplasmic reticulum to the Golgi complex, to examine the mechanisms of cleavage, phosphorylation and sulphation of rat progastrin-derived peptides. Biosynthetic products were detected after immunoprecipitation using antibodies specific for the extreme C-terminus of progastrin, followed by reversed-phase and ion-exchange h.p.l.c. Gastrin cells incorporated [3H]tyrosine, [32P]phosphate and [35S]sulphate into both progastrin and its extreme C-terminal tryptic (nona-) peptide. Ion-exchange chromatography resolved four forms of the C-terminal tryptic fragment of progastrin which differed in whether they were phosphorylated at Ser96,
INTRODUCTION
Biologically active hormones and neuropeptides are generally produced from inactive precursors by post-translational modifications that typically occur before secretion, and include cleavage of the peptide chain, tyrosine sulphation, serine phosphorylation, glycosylation, C-terminal amidation and Nterminal glutamine cyclization [1] [2] [3] [4] . The precursor of the acidstimulating hormone gastrin, preprogastrin, is a convenient model for the study of post-translational processing mechanisms because it is relatively small (104 residues in the rat), simple (there is a single copy of the sequence defining biological activity) and because several common post-translational modifications, namely cleavage, sulphation, amidation and phosphorylation, occur in a single dodecapeptide sequence which includes the biologically important region of the hormone [5] [6] [7] [8] [9] .
The phosphorylation site in progastrin is of interest because it is immediately adjacent to a pair of arginine residues (Arg94-Arg95), cleavage at which is an early step in the conversion of precursor to active peptide ( Figure 1 ) [9] [10] [11] . The main active products in the rat are peptides of 34, 17 and 16 residues (i.e. G34, G17 and G16) and are produced by further cleavage at Arg57-Arg58, Lys74-Lys75 and Gln76-Arg77 respectively together with amidation of the C-terminal residue (Phe92). The serinephosphorylation site is conserved in all members of the gastrin/ cholecystokinin family sequenced so far. The kinase responsible for phosphorylation at this site is not known, but it is of interest that acidic residues are invariably located at positions 2 and 3 Cterminal to Ser96 ( Figure 1) ; the configuration of serine followed sulphated at Tyr103, both or neither. The specific activity of [3H]tyrosine in the peak that was both phosphorylated and sulphated was higher than in the others. Brefeldin A inhibited the appearance of [3H] tyrosine-labelled C-terminal tryptic fragment but there was an accumulation of labelled progastrin and a peptide corresponding to the C-terminal 46 residues ofprogastrin. Brefeldin A also inhibited incorporation of 32P and 35S into both progastrin and its C-terminal fragment. Thus phosphorylation of Ser96, sulphation of Tyr103 and cleavage at Arg94-Arg95 depend on passage of newly synthesized progastrin along the secretory pathway; as brefeldin A is thought to act proximal to the transGolgi, these processing steps would appear to occur distal to this point. The data also indicate that the stores of unphosphorylated C-terminal tryptic fragment are not available for phosphorylation, implying that this modification occurs proximal to the secretory granule; cleavage is known to occur in the secretory granule which suggests that it occurs after phosphorylation.
at position 2 to the C-terminus by an acidic residue is also found at phosphorylation sites in casein which raises the possibility that physiological casein kinase or a related enzyme might phosphorylate progastrin [12] [13] [14] . Similar potential phosphorylation sites occur immediately adjacent to cleavage points in several other hormone and neuropeptide precursors which are otherwise unrelated to progastrin [10] , e.g. provasoactive intestinal polypeptide, progastrin-releasing peptide, proneuropeptide Y and in the region of chromogranin A giving rise to pancreastatin, indicating that this motif is likely to be of significance in several different systems. One possibility is that phosphorylation in some way influences processing at the adjacent cleavage site, but the relationship between phosphorylation and cleavage remains uncertain, and in particular it is not clear whether Ser96 in progastrin is phosphorylated before cleavage at the adjacent arginine residue or after (or either).
In the case of gastrin and other peptide precursors that are delivered to the regulated pathway of secretion, there is evidence that important steps of cleavage and amidation occur after segregation of precursor forms into immature secretory granules [15] . The fungal metabolite brefeldin A is known to inhibit the passage of material along the secretory pathway from endoplasmic reticulum to Golgi, but there have been relatively few studies of how brefeldin A influences the post-translational processing of hormonal and neuropeptides [16] [17] [18] [19] [20] . We -Phe-GIy-Arg-Arg-Ser-AIa-GIu-GIu-GIu-Asp-Gln-Tyr-Asn L304/L363 Figure 1 Schematic representaton of the structure of rat preprogastrin
The expanded sequence shows the C-terminal tridecapeptide. Note the serine-phosphorylation site immediately adjacent to a pair of arginine residues. The C-terminal tryptic cleavage product of progastrin can also be sulphated at Tyri03. Antibodies L304 and L363 react with progastrin and its C-terminal tryptic fragment. Biologically active gastrins are generated by endo-and carboxy-peptidase cleavage of arginine residues adjacent to the phosphorylation site, and conversion of the glycine-extended product by peptidyl a-amidating mono-oxygenase to peptides C-terminally amidated at Phe92. Further cleavage at Arg57-Arg58 (RR) or Lys74-Lys75
(KK) generates the active products, G34 and Gl7 (a third product, G16, is produced by cleavage of the N-terminal residue of G17). Note that cleavage at positions 57/58 or 74/75 without processing of the C-terminal region of the precursor generates putative biosynthetic intermediates (G34-CFP and G17-CFP) which would be expected to react with antibodies specific for the Cterminus of progastrin. The eluate was dried in vacuo, reconstituted with 2 ml of distilled water and pooled with the C18 eluate. This method has previously been shown to give good recovery of intact progastrin and its C-terminal flanking peptide [10, 11, 24] . Progastrin-derived peptides were further concentrated by immunoprecipitation. Removal of non-specifically precipitated peptides was carried out by a cycle of precleaning in which 50 ,u of non-immune rabbit serum was added followed by 200 ,1 of goat anti-(rabbit IgG). The precipitate was allowed to form at 4°C overnight and was removed by centrifugation (3000 g, 15 min). Progastrin and related peptides were then precipitated from the supernatant by addition of 50 ,1 of antibody L304 and 200,l of goat anti-(rabbit IgG). The rabbit antibody is specific for the C-terminal region of rat progastrin and reacts with both intact progastrin and CFP [9] . Precipitates were recovered by centrifuging at 3000 g for 15 min, extensively washed with icecold 0.02 M phosphate buffer, pH 7.4, and the precipitated gastrin-related peptides were solubilized by boiling with 1 ml of water. The final product was further centrifuged at 100000 g for 60 min at 4°C, and the precipitate discarded.
MATERIALS AND METHODS
The progastrin-related peptides recovered after immunoprecipitation were purified by reversed-phase h.p.l.c. on a PRP-LS column (5 p, 4.6 mm x 250 mm) which was eluted with a gradient from 0 to 28 % acetonitrile in 0.05 M NH4HCO3, pH 7.9. The reversed-phase h.p.l.c. gradient system was calibrated in separate runs with the synthetic C-terminal nonapeptide of rat progastrin [9] , or with intact human progastrin isolated from a gastrinoma [24] . The C-terminal fragments of progastrin in the reversed-phase h.p.l.c. eluates were further separated by ion-exchange h.p.l.c. on a Mono Q column (HR5/5; Pharmacia) equilibrated with 20 mM Tris/HCl, pH 8.2, and eluted with a gradient to 0.5 M NaCl in 20 mM Tris/HCl, pH 8.2. Radioactivity in the column eluates was routinely counted on-line using a Canberra Packard A280 flow radiometer, and a stream splitter was used to recover material for radioimmunoassay or for further chromatography.
Radiolmmunoassay Progastrin-derived peptides in the eluates of reversed-phase and ion-exchange column runs were estimated by radioimmunoassay using antibody L304 or L363 both of which react at the extreme C-terminus of rat progastrin and detect intact progastrin and its C-terminal fragments modified by sulphation of Tyr'03 or phosphorylation of Ser"fi ( Figure 1 ) [9] . In some experiments, column eluates were assayed with antibody L66 which reacts at the extreme N-terminus of G34 [25] . (Figure 2 and 3) . The major peak coeluted with the synthetic C-terminal nonapeptide of rat progastrin, i.e. CFP, the second peak, which was always smaller, co-eluted with progastrin isolated from a gastrinoma. In both cases, the peaks of radioactivity corresponded in retention time to peaks of activity detected by radioimmunoassay using antibody specific for the C-terminus of progastrin. A third peak of radioactivity, which was sometimes barely detectable, emerged approx. 7 min before progastrin. In radioimmunoassays, material with a similar retention time reacted with both antibody specific for the N-terminus of G34 and antibody specific for the Cterminus of progastrin, and so was identified as G34-extended to the C-terminus of progastrin (G34-CFP), i.e. progastrin Cterminal fragment generated by cleavage at Arg67-Arg58. Previous work has established that rat CFP occurs in four forms which are poorly separated on size-exclusion chromatography and reversed-phase h.p.l.c., but readily resolved on ionexchange chromatography; these peptides have been characterized as CFP variants differing in sulphation of Tyr103 and phosphorylation of Ser96 [9] . We found that when the eluates of reversed-phase h.p.l.c. corresponding to CFP were further purified by ion-exchange chromatography, four peaks were resolved which were labelled with [3H]tyrosine and also contained material detected by radioimmunossay (Figure 4) . The least acidic peptide (I) co-eluted with the synthetic C-terminal nonapeptide of rat progastrin and so was identified as the unmodified peptide. The two most acidic peptides (III and IV) were also labelled in incubations in [35S] sulphate and so were identified as being sulphated on Tyr103, the most acidic peptide (IV) was also labelled with 32P and so was both sulphated and phosphorylated (Figure 4) . These assignments are consistent with previous conclusions based on the results of digestion with alkaline phosphatase and aryl sulphatase [9] . Peak II has previously been shown to consist of phosphorylated unsulphated peptide [9] (Figure 4 ), suggesting that this form might be generated preferentially. In order to determine whether there might be dephosphorylation (or desulphation) in the present experiments, tissues were incubated first with [3H]tyrosine for 2 h, and then chased with medium containing unlabelled tyrosine. After 3 h chase, there was a 20 % reduction in specific radioactivity of peak IV, and increases in specific radioactivity of peaks I-III ( Figure 5 (Figures 2 and 3) . The radioimmunoassay data show four peaks (I-IV). Note that peak IV is labelled with 3H, 32P and 35S; peak Il is labelled with 3H and 35S but not 32p; peaks and 11 show incorporation of 3H; from previous work [9] , peak 11 is known to be phosphorylated but not sulphated, and presumably in the present experiments incorporation of radiolabelled phosphate was below the limit of detection. The rate of flow was 1.0 ml/min; 85% of the stream was split for on-line counting and the remainder taken for radioimmunoassay. The up-date time for counting was progastrin along the secretory pathway to a point beyond the site of action of brefeldin A.
RESULTS

Identificafton of progastrin-derived peptides
DISCUSSION
Brefeldin A causes the collapse of the Golgi complex into the rough endoplasmic reticulum, and so disrupts the forward movement of newly synthesized secretory proteins [16, 19, 20] . There is evidence for redistribution of membrane proteins from cis-, medial-and trans-Golgi into rough endoplasmic reticulum, but not from the trans-Golgi network [18] . Although there are also other potential sites of action of brefeldin A, e.g. interactions between the endosomal compartment and the trans-Golgi network [26] , the present data are best explained by a failure to transport newly synthesized progastrin from endoplasmic reticulum to Golgi complex.
Previous work has shown that progastrin is converted into its active products in immature secretory granules [15] . The major cleavage sites in progastrin are pairs of basic residues, and it seems likely that endopeptidases of the KEX2 family, e.g. PC2 or PC3, are responsible for cleavage [27] [28] [29] [30] . The localization of endopeptidase cleavage to the immature secretory granule implies that endopeptidases must be produced, transported and segregated into the regulated pathway of secretion in parallel with their substrates. It is interesting that there was little or no cleavage of Arg94-Arg95 in brefeldin A-treated cells, whereas the cleavage of progastrin that was sometimes observed at Arg57-Arge8 was apparently uninfluenced by brefeldin A. Evidently therefore there is a differential effect of brefeldin A on cleavage at the two sites. This observation suggests that there is a strict requirement for access of the precursor beyond the trans-Golgi for completion of the functionally important cleavage which generates the biologically active C-terminal part of gastrin, whereas the conditions for cleavage at the N-terminus of G34 are less stringent. of different progastrin-derived peptides determined by radioimmunoassay using antibody specific for the C-terminus of progastrin. Total immunoreactives in the control and brefeldin Atreated samples were similar (control: 18.5 pmol; brefeldin A: 17.8 pmol). Values are means + S.E.M. (n in parentheses). Comparisons were made by the paired t test: *P < 0.01, *P < 0.05, ***P < 0.001, compared with control values.
Control
Brefeldin A-treated
Labelled peptide CFP (6) G34-CFP (6) Progastrin (6) By radioimmunoassay CFP (7) G34-CFP (7) Progastrin (7) 66.5+ 6. Approx. 50 % of native CFP occurs in the unphosphorylated form; at least some of the latter may arise by dephosphorylation ( Figure 5 ). In principle, endogeneous kinases could act on either progastrin or CFP. Because brefeldin A inhibited phosphorylation of CFP, it would appear that only newly synthesized peptide is available for the action of kinases, and consequently that these are unable to act on the pool of unphosphorylated CFP that is already contained in secretory granules. Similarly it would appear that sulphation is limited to newly synthesized peptide. In the case of other secretory proteins, e.g. the vitellogenins, there is evidence that phosphorylation occurs just before secretion [31] ; vitellogenin is probably secreted via the constitutive pathway which could place the kinase in the distal regions of the Golgi. Recently it has been reported that, in PC12 cells, brefeldin A inhibited sulphation but not phosphorylation of two proteins that are segregated to the regulated pathway of secretion, Comparisons were made by the Mann-Whitney Utest: **P < 0.05, ***P < 0.001, compared with control values.
Brefeldin A-treated [32] . The present observation that brefeldin A inhibited sulphation of progastrinderived peptides is consistent with these observations. However, it is not yet clear why brefeldin A acts differently on phosphorylation ofthe chromogranins compared with the progastrin-derived peptides. There are, however, multiple potential phosphorylation sites in the granins; it is possible that the kinase acting on progastrin-derived peptides is not the same as that acting on the granins and that the two have a differential location.
The results of the present study indicate that phosphorylation, sulphation and Arg94-Arg95 cleavage of progastrin occur at a site 
K0
distal to that at which brefeldin A acts, i.e. beyond the transGolgi cisternae. The pool of unphosphorylated CFP in secretory granules is not, however, labelled with [32P]phosphate in the presence of brefeldin A which suggests that phosphorylation occurs proximal to the secretory granule. As cleavage occurs after delivery of progastrin to the secretory granule [15] , it would appear that progastrin is phosphorylated before cleavage, probably in the trans-Golgi network. This conclusion, together with the observation that the progastrin phosphorylation site is well conserved, suggests a functional role for prohormone phosphorylation in the control of the events associated with precursor maturation.
